Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glomerulosclerosis, Focal Segmental × Adalimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Spondylitis, Ankylosing 1 Sarcoidosis 1 Nephrotic Syndrome 1 Nephrosis, Lipoid 1 Macular dystrophy, corneal type 1 1 Kidney Diseases 1 Glomerulosclerosis, Focal Segmental 1 Dupuytren Contracture 1 Crohn Disease 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

University of Michigan

Phase 2 Completed

7 enrolled 12 charts

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡